Endomorphin-l (EM-I) is an endogenous opioid peptide selectively binding to J1 opioid receptors (MORs). Besides its analgesic effects on the central nervous system (CNS), it has been recently reported that EM-l can cross the blood-brain barrier (BBB) and diffuse into the blood, behaving as an analgesic/ anti-inflammatory molecule on peripheral tissues, thus leading to the hypothesis that it could represent a soluble modulator of immune cell functions. Interestingly, nothing is known about its possible effects on monocytes, the main circulating cell-type involved in those systemic responses, such as fever and septic states, involving the release of high amounts of pyrogenic inflammatory factors. The aim of this work is to evaluate possible EM-leffects on Iipopolisaccharide (LPS)-stimulated THP-I monocytes in terms of the production of inflammatory mediators and the instauration of a hyporesponsive-Iike phenotype which is a main feature of systemic inflammatory responses, and on the development of peripheral monocytes to DC. Our data demonstrate for the first time that EM-I is able to inhibit both LPS-stimulated monocyte activation, in terms of arachidonic acid, PGE 2 , ROI and NO z production and instauration of a hypo responsive phenotype without any macroscopic effect on DC development. These data support the hypothesis that EM-I could be involved in modulating monocyte functions during systemic inflammatory reactions, also providing new evidence for its eventual clinical application in endotoxic states.
from the central nervous system (4) (5) . Coherently, EM-l presence has been traced in many peripheral inflamed tissues, where it has proven to significantly decrease sensory neuron firing rate (6) (7) and, most notably, to significantly suppress the release of inflammatory factors from macrophages, which mainly accounts for the development of any algesic reaction occurring in peripheral tissues (6) .
Even though this evidence allows to hypothesize a new role for EM-l as a neuro-endocrine regulator of immune functions, it still lacks any knowledge about its possible effects on other leukocytes expressing Il opioid receptors (MaRs) (7) . Among these, monocytes would be a favorable target for EM-l anti-inflammatory activity, for they are the major cell type involved in systemic inflammatory reactions having a key role in inducing fever and Systemic Inflammatory Reaction Syndrome (SIRS) (8) (9) . In fact, when monocytes are stimulated by high amounts of pathogen products (as happens in septic states), an excessive intravascular release of inflammatory mediators such as prostaglandins (PGs), leukotrienes (LTs) and oxidant molecules can result in multiple organ failure and host death (8) (9) (10) .
Moreover, an additional alteration of monocyte functions can occur during septic states: as a consequence of a profound inflammatory activation, in fact, monocytes can develop a hyporesponsive phenotype, which makes them insensitive to new stimulation (11). Such a phenomenon, resulting in a diffused immunoparalytic state, is also detrimental as it exposes the host to a facilitated colonization by invading pathogens (11). Finally, as a further alteration of monocyte functions during septic states, it has been recently postulated that the excessive activation of these cells could impair their development to dendritic cells (DCs), the major antigen-presenting cells (APCs), which would then spread immunoparalysis to the specific compartment of the immune response (10, (12) (13) .
Thus, in the view of a supposed role for EM-1 as a new immunosuppressive molecule, the aim of this work is to investigate possible EM-l effects on a model of intense monocyte activation consisting of human THP-l cells pulsed with high lipopolysaccharide (LPS) doses in order to reproduce in vitro a situation comparable to an in vivo septic state. In this context, this study evaluates EM-l effects on the production of systemic inflammatory mediators such as PGs, LTs and Reactive Oxygen and Nitrogen Intermediates (ROl and NOl, respectively), also assessing its possible effects in preventing the development of monocyte hyporesponsivity and in driving monocyte differentiation to DCs.
MATERIALS AND METHODS

Cell culture
The human monocytic cell line THP-1 was obtained from American Type Culture Collection (Manassas, VA) and cultured at 37°C in 5% C02 with RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), Lglutamine (2 mM), streptomycin (100 ug/ml), penicillin (100 U/ml), sodium pyruvate (100 ug/ml), herein referred to as "complete medium". In all experiments, to determine cell viability, monocyte cultures were stained with trypan blue at specific time-points after treatment with different reagents. Stained vs living cells were counted under a microscope using a Neubauer modified chamber.
rHJ-Arachidonic acid release assays lx10 6 THP-l cells/well were seeded in complete medium and labelled for 3 h with 1 llCi [3H]-arachidonic acid (AA, spec. act. 202,4 Ci/mmol) at 37°C, as previously described (14) . To remove non-specific binding of PH]-AA to cell surface prior to agonist stimulation, cells were recollected by centrifugation at 1200 rpm for 5 min and washed twice in serum-free medium prior to re-suspension in fresh complete medium. In experiments involving a single LPS pulse, cells were stimulated with different LPS (1-10 ug/ml) and EM-l concentrations (10-6 -1O-12M) for 24 h. When requested, cells were also incubated with 10 llM methyl arachydonil fluorophosphate (MAFP, a selective cPLA 2 inhibitor) for 30 min, with 1O-8M diphenylene iodinium (DPI, a specific NADPH oxidase inhibitor) for 30 min or with 1O-6M naloxone (a selective MOR inhibitor) for 2 h before LPS stimulation. In experiments involving two LPS pulses, cells were stimulated once with 10 ug/ml LPS for 24 h plus or not 1O-6M EM-I, recollected by centrifugation, re-suspended in complete medium and then stimulated for further 24 h with 10 ug/ml LPS. At each time-point, supernatants were collected and 100 III aliquots were added to 3 ml Optifluor and analyzed by a liquid scintillator counter.
Measurement of Leukotriene B 4 and Prostaglandin £2 release
1x10 6 cells/well were challenged with 10 ug/ml LPS in the presence or absence of 1O-6M EM-1 for 24 h, and supernatants were collected by centrifugation at 1200 rpm for 5 min. Leukotriene B4 (LTB4) and Prostaglandin E z (PGE z ) levels in the medium were then assessed by enzyme immunoassay (EIA, Cayman Chemical) following the manufacturer's instructions. Briefly, 50 III LTB 4 or PGE z standard or samples were added to the pre-coated mouse monoclonal anti-rabbit IgG macrotitre plates for LTB 4 or to the pre-coated goat polyclonal antimouse IgG macrotitre plates for PGE r Subsequently, 50 III LTB 4 or PGE z tracer and 50 III monoclonal LTB 4 or PGE z antiserum were added into each well and the mixture was incubated overnight at 4°C. After incubation, the content of each well was removed and the wells were washed 5 times with PBS buffer containing 0.05% Tween-20. An aliquot of200 IIIEllman's reagent was added to each well, and the mixture was incubated for 2 h at room temperature with occasional shaking. The solution optical density (O.D.) was determined by a multi-well spectrophotometer (ELISA reader) at 405 nm. LTB 4 and PGE z concentration in each sample was calculated as the concentration corresponding to sample's O.D. values plotted on their respective standard built-in curves.
Evaluation ofRO!production by 2', 7'dichlorofluorescein diacetate (DCF-DA) fluorescence lx10 6 cells were seeded in serum-free medium to prevent DCF-DA degradation by serum components and loaded with the fluorescent dye DCF-DA (10 11M) for 30 min at 37°C in the dark. Upon diffusion through the cell membrane, DCF-DA is hydrolyzed by intracellular esterases to non-fluorescent DCF, which is then rapidly oxidized to highly-fluorescent DCF in the presence ofROL The DCF fluorescence intensity, thus, is proportional to the amount of intracellular ROI formed. After the incubation with the dye, cells were recollected and centrifuged for 5 min at 1200 rpm at room temperature. In experiments involving a single LPS pulse, the cells were re-suspended in serum-free medium and challenged with 10 ug/ml LPS for different experimental times (5 -180 min) or with 10 ug/ml LPS plus different EM-l concentrations (10-6 -1O-1ZM) for 45 min. When requested, monocytes were incubated with 10-8M DPI for 30 min or with 10-6M naloxone for 2 h prior to LPS pulse. Additionally, cells were also incubated with 10 ug/ml LPS plus different EDTA concentrations (5 -20 mM) for 45 min. In experiments involving a double LPS pulse, the cells were stimulated with 10 ug/ml LPS plus or not 10-6M EM-I for 24 h prior to DCF-DA loading, as previously described. Cells were then stimulated with further 10 ug/ml LPS for 45 min. Cell fluorescence was measured under continuous magnetic stirring and controlled temperature (37°C) in a computer-aided Perkin-Elmer luminescence spectrometer (Model LS 50 b), with excitation wavelength set at 485 nm and emission wavelength set at 530 nm using 5 and 10 nm slits, respectively, for each light path.
Evaluation ofnitrite (NO) production by Griess reaction
In experiments involving a single LPS stimulation, 3.5 x 10 6 cells/well were seeded in complete medium and pulsed with 10 ug/ml LPS in the presence or absence of EM-I (10-6M _1O-1ZM) for 24 h. In experiments involving a double LPS stimulation, 1.75 x 10 6 cells/well were seeded in complete medium and challenged with 10 ug/ml LPS plus or not 10-6M EM-l for 24 h, recollected by centrifugation at 1200 rpm for 5 min, re-suspended in complete medium and stimulated for further 24 h with 10 ug/ml LPS. At each time-point, supernatants were collected, and nitrite (N0z) levels in the medium were evaluated by mixing equal volumes of supernatans and Griess modified reagent in a macrotitre plate. When requested, cells were incubated with 10-8M DPI prior or with 10-6M naloxone for 2 h prior to LPS stimulation. Upon incubation for 30 min at room temperature, the presence of Nt), in the samples determines the formation of a fluorescent dye sensible to stimulation with a laser beam set at 550 nm. NO z concentration in each sample was thus desumed by plotting the average O.D. on a standard curve prepared with sodium nitrite (NaNO z ' 0.43 -65 11M) before each experiment, and each sample was divided by its relative control (arbitrary set to 100%) and then multiplied by 100 to obtain the relative increase.
Peripheral monocytes purification and Dendritic Cells (DCs) generation
Peripheral Blood Mononuclear Cells (PBMCs) were isolated from buffy-coats ofhealthy donors with ages ranging between 18 and 40 years, kindly provided by "La Sapienza" University Transfusion Service. Cells were separated by density gradient centrifugation using Lympholyte-H, and monocytes were then positively separated using anti-CD14-labeled magnetic beads (MACS) and re-suspended in RPMI-I640 supplemented with 10% foetal calf serum (FCS), L-glutamine (2 mM), gentamycin (10 ug/ml.), Hepes buffer (10 mM), sodium pyruvate (0.1 M) and nonessential aminoacids (0.1 M). Monocytes were then washed and cultured with fresh complete medium for 5 days in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF, 200 U/ml) and IL-4 (10 ng/ml) and in the presence or absence of 10-6M EM-I to generate immature DCs (imDCs). imDCs were finally incubated for further 48 h with I ug/ml LPS to induce final maturation according to Martino et al. (15) .
Fluorochrome-Activated Cell Sorter (FACS) Analysis
The ...~0
C LPS EM-1 significant effect, highlighting the involvement of this enzyme in LPS-stimulated AA release. In order to evaluate possible EM-I effects on LPS-stimulated AA release, cells were stimulated with LPS in the presence or absence of different EM-l concentrations (10-6 - 1O-12M) for 24 h. Data shown in Fig. la demonstrate that the highest EM-l concentrations (10-6 and 1O-8M) were able to significantly inhibit LPS-induced AA release, while lower concentrations were ineffective.
To evaluate possible EM-l effects on the production of major arachidonic acid-derived inflammatory factors, the levels of PGE 2 and LTB 4 
by Newman-Keuls test, in respect to LPS-treated cells (LPS)
Reagents RPMI-1640, FBS, glutamine, pyruvate, penicillin, streptomicin and sodium pyruvate were acquired from Cambrex. FCS was acquired from Hyclone. Lympholyte-H was acquired from Cederlane. Anti-CDI4-MACS were acquired from Milteny Biothec. GM-CSF and IL-4 were acquired from Euroclone. Gentamycin, (3H]-AA, LPS, DCF-DA, trypan blue, EM-I, non-essential aminoacids, Hepes buffer and Griess modified reagent were acquired from Sigma Aldrich. Monoclonal EIA kits for LTB 4 and PGE 2 were acquired from Cayman Chemicals. FITC-, PE-or APC-conjugated mAbs were acquired from Becton Dickinson Bioscience.
-DC-SIGN were used to characterize DCs population. The cells were stained with either FITC-, PE-or APCconjugated rnAbs and analyzed using a FACScalibur running Cellquest Software (Becton Dickinson, Mountain View, CA, USA).
RESULTS
Statistical analysis
Data distribution was preliminarily verified by the Kolmogorov-Smimov test, and data sets were analyzed by one-way analysis of variance (ANOVA), followed by Newman-Keuls test. Differences were regarded as significant when P-value was less than 0.05. Quantitative data were expressed as the percentile mean±S.D. of at least four replicate determinations each performed in triplicate, except where otherwise indicated.
Endomorphin-I (EM-i) effects on the release of Arachidonic Acid (AA), Prostaglandin E 2 (PGE) and Leukotriene B 4 (LTB) from LPS-stimulated THP-i monocytes
Preliminary experiments were performed to evaluate THP-I cells response to high LPS doses (1, 5 or 10 ug/ml) in terms of arachidonic acid (AA) release. All tested LPS doses determined a significant AA release (data not shown), with a maximum effect at 10 ug/ml which was then chosen as the dose for cell stimulation in all subsequent experiments. Moreover, since cytosolic phospholipase A 2 (cPLA) is one of the major enzymes involved in the mobilization of AA from membrane stocks to the extracellular spaces (16) , experiments were performed to evaluate its possible involvement in LPS-stimulated AA release. The data shown in Fig.  I a show that, when cells were pretreated with MAFP (a selective cPLA 2 inhibitor), LPS did not exert any LTB 4leve!s, which remained equal to control.
LPS-induced ROJ production is Ca 2 +-dependent and is requiredfor both AA and N0 2 release from THP-l monocytes
Since it has been reported that NADPH oxidasedependent ROI production can act as a signaling mechanism leading to cPLA z activation and NO z production (18) (19) , experiments were performed to evaluate whether LPS-induced release of AA and NO z was affected by NADPH oxidase inhibition. Data shown in Fig. 3 demonstrate that, when ROI production was inhibited by DPI, a) no AA release nor b) NO z production could be observed after LPS pulse, demonstrating that ROI production is a priming factor for the subsequent release of both AA and NO z . Moreover, since it has been reported that
EM-l suppresses LPS-stimulated oxidant molecules production in THP-l monocytes
To investigate the possible effects of EM-l on LPS-induced ROI production, the cells were stimulated with LPS plus or not EM-l (10-6 -10-IZM) for 45 min, a time-point at which a maximal ROI production occurs as demonstrated from preliminary time course experiments (5 min -3 h) on ROI production kinetics shown in Fig. 2 inset. In addition, to assess a possible involvement of NADPH oxidase, a major enzyme involved in ROI production in phagocytes (17), experiments were performed pre-treating cells with DPI, a selective NADPH oxidase inhibitor. Data in Fig. 2a show that no significant ROI production could be observed in DPI-pretreated cells following LPS pulse, highlighting the involvement of NADPH oxidase in ROI production. Moreover, data in Fig. 2a also show that the highest EM-1 concentrations (10-6 and 10-8M) were able to significantly inhibit LPS-stimulated ROI production, while lower concentrations were ineffective.
In separate experiments, cells were also stimulated with LPS plus or not EM-l (10-6 -10-lZM) for 24 hand NO z levels of in the medium were evaluated. Data shown in Fig. 2b demonstrate that only the highest EM-1 concentration (10-6M) resulted in a significant inhibition of LPS-induced NO z production, while lower concentrations did not determine any significant effect. in the medium were evaluated upon cell stimulation with LPS plus 10-6M EM-1 for 24 h. The data shown in Fig. 1b demonstrate that LPS determined a significant increase in PGE z production, which was abrogated by the simultaneous incubation with the peptide. Conversely, both the incubation with LPS alone or with LPS + EM-l did not exert any effect on 
EM-l prevents the development ofa hyporesponsive phenotype
Monocyte hyporesponsivity triggered by repeated stimulations is a major pathological event characterizing the late phases of systemic inflammatory syndromes, which exposes the host to further aggressions (11). It would therefore be of key clinical importance to avoid such an aberrant derivation of monocyte functions (10) . Since our previous data showed the efficacy of EM-l administration in suppressing THP-l cells activation, we have developed a model of monocyte Ca 2 + is involved in LPS-induced ROI production (20) , experiments were performed in the presence of different EDTA concentrations (5 -20 mM) to deplete extracellular Ca 2 +. Data in Fig. 3c show that LPS-induced ROI production was dose-dependently inhibited by EDTA, 20 mM being the most effective concentration, allowing us to hypothesize that Ca 2 + currents are a priming factor in LPS-triggered signaling mechanisms.
EM-l effects are mediated by~opioid receptor (MOR) activation
In order to evaluate whether EM-I effects were mediated by J..l opioid receptor (MaR), experiments were performed incubating cells with naloxone, a specific MaR inhibitor, before stimulation with LPS plus EM-I. Data in Fig. 4 show that naloxone pretreatment blocked the inhibitory effect of 10- hyporesponsivity induced by a double overnight pulse with high LPS doses, and tested possible EM-I effects in preventing the establishment of such a phenotype. Data shown in Fig. 5 demonstrate that a double LPS pulse (LPS+LPS) results in the absence of both AA release (a) and ROI production (b) in respect to the cells stimulated with a single LPS pulse (LPS), while an abnormal increase in NO z ' whose levels were higher than the ones characterizing single LPS-stimulated monocytes, could be observed (c).
Basing on these results, then, we tested whether the addition o~1O-6M EM-l during the first LPS pulse could re-establish monocyte responses to the second pulse. Data shown in Fig. 5 demonstrate that the addition of EM-l allows monocytes to preserve their ability to respond to the second LPS pulse (LPS+EM-l+LPS), as demonstrated by a restored AA release (a) and ROI production (b), with a concomitant decrease in NO z levels which tended to be equal to the ones characterizing single LPSstimulated monocytes (c).
EM-l effects on dendritic cell (DC) generation
Since it has been recently reported that an alteration in monocyte inflammatory metabolism plays a key role in controlling both the physiological and the pathological development to DCs (10-13), experiments have been performed to evaluate possible EM-I interference on peripheral monocyte development to DCs in terms of the expression of specific transductional (CD25, DC-SIGN), costimulatory (CD80, CD86) and immuno-stimulatory (HLA-I, HLA-DR) markers. Data in Fig. 6 show that the addition of 1O-6M EM-I to developing DCs does not significantly alter the expression of any chosen marker.
DISCUSSION
Endomorphin-l (EM-I) is an endogenous peptide behaving as an opiate drug on the nervous system (1), being mainly endowed with endogenous leucocyte subpopulations, in fact, have been demonstrated to actively produce endomorphins, which in turn could contribute to decrease the sensory neuron firing rate (22) (23) . Moreover, leucocytes have been also demonstrated to express MaRs, thus allowing to hypothesize that EM-1 could exert multiple analgesic/anti-inflammatory effects in both an autocrine and paracrine fashion (22) (23) (24) . Notably, recent evidence demonstrated that EM-1 can actively cross the blood-brain barrier (BBB), thus diffusing into the blood and possibly reaching distant inflamed tissues (4) (5) , also affecting the functions of circulating MaR-expressing cells.
In this context, however, it still lacks any knowledge about EM-1effects on circulating cells belonging to the systemic compartment of the immune response, such as monocytes. Monocytes, in fact, represent the first defense line against invading pathogens, and their ability to release a vast range of pro-inflammatory molecules in the blood flow is a major event in the induction of systemic reactions (8) (9) . However, monocytes activated by an excessive pathogenic stimulus release huge amounts of . inflammatory molecules leading to life-threatening multiple organ failure (9) . Moreover, a generalized immunosuppressed state (a condition usually referred to as hyporesponsivity), generally establishes itself after an intense inflammatory response (11). Such a also for the host, and it is mainly believed to depend on monocyte hyporesponsivity or on an altered monocyte differentiation to DC (10) (11) 13) .
On the basis of such evidence, therefore, the aim of this work is to evaluate possible EM-l immunomodulatory effects on a model of intense monocyte activation consisting of THP-l cells challenged with high LPS doses, in an attempt to recreate in vitro a situation occurring in vivo during septic states. The use of a reliable human monocyte model (25) in this experimental framework allowed us to avoid the inter-and intra-specific variability which usually arises in human or animal peripheral blood mononuclear cells (PBMCs) (26) , thus facilitating the interpretation of extrapolated data.
In this context, our data prove for the first time that EM-l exerts a significant inhibitory activity on monocytes, for it suppressed the production of chosen activation markers, comprising ROI, NO z ' AA and PGEz-Notably, other evidence analgesia (antinociception) by means of its ability to bind to 1..1. opioid receptors (MaRs) (21) . Coherently, EM-1 has been traced in those areas of the brain and the central nervous system (CNS) which have a regulatory activity on the body pain perception (2, 21) . Interestingly, outside the CNS, the immune system is a major EM-l producing site: different seems to be of particular interest: the use of high LPS doses, in fact, resulted in the alteration of monocyte AA metabolism, which was shifted from an inflammatory (i.e., LTB 4-producing) profile to an immunosuppressive (i.e., PGE 2-producing) one. Intriguingly, these observations provide both good feedback on our experimental model, for they resemble recent data obtained from macrophages endowed with systemic inflammatory syndromes and immunosuppression (27) , and also possibly explain such a phenomenon as a consequence of a previously-altered monocytic state.
Basing on these observations, we subsequently tested whether, in our experimental model, hyporesponsivity could be observed after sequential overnight incubation of these cells with two high doses of LPS pulses. Interestingly, as a response to such a protocol, cells did not respond to the second pulse in terms of both ROI production or AA release, while an abnormal N0 2 production, which is considered to be immunosuppressive (27) (28) , was observed. In such a simple desensitization model, EM-l proved to block both AA release and ROI production, concomitantly normalizing N0 2 production.
Interestingly, considering the immunosuppressive effects of excessive N0 2 production (27-28), our data suggest that EM-l could modulate monocyte responsivity through the modulation of N0 2 levels. Furthermore, our data provide the first evidence of the mechanism by which EM-1 could exert its effects on LPS-stimulated cells. We demonstrate, in fact, that LPS induces a rapid NADPH oxidasedependent ROI production, which in tum activates both cytosolic PLA 2 (cPLA 2)-dependent AA release and N0 2 production. The whole pathway seems to be Ca't-dependent, since no ROI production could be observed when the cells were pulsed with LPS in the presence of EDTA. In this context, the observed ability of EM-l to suppress LPS signaling cascade could be easily linked to a decrease in the intracellular Ca 2 + content, since it has already been demonstrated that MaR activation is coupled to calcium current inhibition (29) .
Finally, since any alteration in DCs is likely to deregulate the inflammatory reactions and to spread immunosuppression (30), we analyzed EM-I effects on DC showing that, when the peptide was added together with GM-CSF and IL-4 to developing DCs, no significant effects could be observed on their specific receptor set. These observations suggest that EM-I immunosuppressive activities are not extended to DC development, thus providing the evidence that EM-1 should not hamper the development of specific immune responses.
Taken together, our data represent the first characterization of EM-I effects on monocytes, also providing clues for a possible EM-I clinical application in inflammatory pathologies and as a useful combination to an antibiotic prophylaxis in septic states.
